Which has higher valuation & earnings, CRBP or CLYM?

Climb Bio is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is CRBP or CLYM more profitable?

Climb Bio's return on equity of -31.45% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% Climb Bio N/A -31.45% -30.39%

Does the media favor CRBP or CLYM?

In the previous week, Corbus Pharmaceuticals had 5 more articles in the media than Climb Bio. MarketBeat recorded 7 mentions for Corbus Pharmaceuticals and 2 mentions for Climb Bio. Climb Bio's average media sentiment score of 1.87 beat Corbus Pharmaceuticals' score of 0.03 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, CRBP or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is CRBP or AVTE more profitable?

Corbus Pharmaceuticals' return on equity of -70.89% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% Aerovate Therapeutics N/A -90.19% -77.47%

Does the media prefer CRBP or CRMD?

In the previous week, Corbus Pharmaceuticals had 5 more articles in the media than CorMedix. MarketBeat recorded 7 mentions for Corbus Pharmaceuticals and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.26 beat Corbus Pharmaceuticals' score of 0.03 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral CorMedix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ACRS or CRBP?

In the previous week, Aclaris Therapeutics had 7 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 7 mentions for Corbus Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 0.98 beat Corbus Pharmaceuticals' score of 0.03 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corbus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor CTMX or CRBP?

In the previous week, Corbus Pharmaceuticals had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 7 mentions for Corbus Pharmaceuticals and 3 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.18 beat Corbus Pharmaceuticals' score of 0.03 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Corbus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Corbus Pharmaceuticals (CRBP) Competitors

$7.38 -0.16 (-2.12%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$7.49 +0.11 (+1.49%)

As of 07:00 AM Eastern

Compare

CRBP vs. CLYM, AVTE, CRMD, ACRS, and CTMX

Should you buy Corbus Pharmaceuticals stock or one of its competitors? MarketBeat compares Corbus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corbus Pharmaceuticals include Climb Bio (CLYM), Aerovate Therapeutics (AVTE), CorMedix (CRMD), Aclaris Therapeutics (ACRS), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry.

How does Corbus Pharmaceuticals compare to Climb Bio?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Corbus Pharmaceuticals currently has a consensus price target of $42.00, suggesting a potential upside of 469.11%. Climb Bio has a consensus price target of $20.30, suggesting a potential upside of 94.44%. Given Corbus Pharmaceuticals' higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

In the previous week, Corbus Pharmaceuticals had 5 more articles in the media than Climb Bio. MarketBeat recorded 7 mentions for Corbus Pharmaceuticals and 2 mentions for Climb Bio. Climb Bio's average media sentiment score of 1.87 beat Corbus Pharmaceuticals' score of 0.03 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Climb Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Climb Bio is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Climb Bio's return on equity of -31.45% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Climb Bio	N/A	-31.45%	-30.39%

Corbus Pharmaceuticals has a beta of 2.57, indicating that its share price is 157% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Climb Bio beats Corbus Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Aerovate Therapeutics?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Corbus Pharmaceuticals' return on equity of -70.89% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Corbus Pharmaceuticals currently has a consensus target price of $42.00, indicating a potential upside of 469.11%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Corbus Pharmaceuticals is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Corbus Pharmaceuticals has a beta of 2.57, suggesting that its stock price is 157% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

In the previous week, Corbus Pharmaceuticals had 7 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 7 mentions for Corbus Pharmaceuticals and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.67 beat Corbus Pharmaceuticals' score of 0.03 indicating that Aerovate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Neutral
Aerovate Therapeutics	Positive

Summary

Corbus Pharmaceuticals beats Aerovate Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to CorMedix?

Corbus Pharmaceuticals (NASDAQ:CRBP) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

CorMedix has a net margin of 45.25% compared to Corbus Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
CorMedix	45.25%	45.57%	24.76%

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CorMedix has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
CorMedix	$311.71M	2.07	$163.05M	$2.13	3.86

Corbus Pharmaceuticals presently has a consensus target price of $42.00, suggesting a potential upside of 469.11%. CorMedix has a consensus target price of $15.00, suggesting a potential upside of 82.26%. Given Corbus Pharmaceuticals' higher probable upside, equities analysts clearly believe Corbus Pharmaceuticals is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Corbus Pharmaceuticals had 5 more articles in the media than CorMedix. MarketBeat recorded 7 mentions for Corbus Pharmaceuticals and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.26 beat Corbus Pharmaceuticals' score of 0.03 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
CorMedix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corbus Pharmaceuticals has a beta of 2.57, suggesting that its share price is 157% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

Summary

CorMedix beats Corbus Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Aclaris Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	78.84	-$64.92M	-$0.56	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

In the previous week, Aclaris Therapeutics had 7 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 7 mentions for Corbus Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 0.98 beat Corbus Pharmaceuticals' score of 0.03 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corbus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aclaris Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market.

Corbus Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

Aclaris Therapeutics presently has a consensus price target of $11.50, suggesting a potential upside of 160.18%. Corbus Pharmaceuticals has a consensus price target of $42.00, suggesting a potential upside of 469.11%. Given Corbus Pharmaceuticals' higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Aclaris Therapeutics beats Corbus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

CytomX Therapeutics presently has a consensus price target of $12.10, suggesting a potential upside of 275.78%. Corbus Pharmaceuticals has a consensus price target of $42.00, suggesting a potential upside of 469.11%. Given Corbus Pharmaceuticals' higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

CytomX Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.57, meaning that its share price is 157% more volatile than the broader market.

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 6.6% of CytomX Therapeutics shares are held by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Corbus Pharmaceuticals had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 7 mentions for Corbus Pharmaceuticals and 3 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.18 beat Corbus Pharmaceuticals' score of 0.03 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Corbus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Corbus Pharmaceuticals has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

CytomX Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.19	-$17.37M	-$0.41	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

Summary

CytomX Therapeutics beats Corbus Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Corbus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBP vs. The Competition

Export

Metric	Corbus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$139.70M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-1.27	17.69	22.17	24.18
Price / Sales	N/A	302.27	524.01	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	0.88	3.85	9.78	6.72
Net Income	-$78.54M	$75.85M	$3.57B	$337.19M
7 Day Performance	-3.40%	-3.99%	-2.50%	-0.75%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	-12.87%	19.65%	26.49%	33.09%

Corbus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBP Corbus Pharmaceuticals	4.4195 of 5 stars	$7.38 -2.1%	$42.00 +469.1%	-11.1%	$139.70M	N/A	N/A	40
CLYM Climb Bio	3.3229 of 5 stars	$11.35 +3.2%	$20.30 +78.9%	+709.3%	$649.90M	N/A	N/A	9	Positive News
AVTE Aerovate Therapeutics	N/A	$22.21 -5.3%	N/A	+146.5%	$643.76M	N/A	N/A	20	Gap Up High Trading Volume
CRMD CorMedix	3.5038 of 5 stars	$8.11 +1.6%	$15.00 +85.0%	-34.7%	$636.23M	$311.71M	3.81	30	Positive News
ACRS Aclaris Therapeutics	3.7356 of 5 stars	$4.53 +0.2%	$11.29 +149.1%	+200.7%	$632.66M	$7.83M	N/A	100	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBP) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. CLYM, AVTE, CRMD, ACRS, and CTMX

How does Corbus Pharmaceuticals compare to Climb Bio?

Summary

How does Corbus Pharmaceuticals compare to Aerovate Therapeutics?

Summary

How does Corbus Pharmaceuticals compare to CorMedix?

Summary

How does Corbus Pharmaceuticals compare to Aclaris Therapeutics?

Summary

How does Corbus Pharmaceuticals compare to CytomX Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. CLYM, AVTE, CRMD, ACRS, and CTMX

How does Corbus Pharmaceuticals compare to Climb Bio?

Do analysts prefer CRBP or CLYM?

Does the media favor CRBP or CLYM?

Which has higher valuation & earnings, CRBP or CLYM?

Is CRBP or CLYM more profitable?

Which has more volatility & risk, CRBP or CLYM?

Do institutionals & insiders have more ownership in CRBP or CLYM?

Summary

How does Corbus Pharmaceuticals compare to Aerovate Therapeutics?

Which has preferable earnings & valuation, CRBP or AVTE?

Is CRBP or AVTE more profitable?

Do institutionals and insiders have more ownership in CRBP or AVTE?

Do analysts rate CRBP or AVTE?

Which has more volatility & risk, CRBP or AVTE?

Does the media prefer CRBP or AVTE?

Summary

How does Corbus Pharmaceuticals compare to CorMedix?

Is CRBP or CRMD more profitable?

Do institutionals & insiders hold more shares of CRBP or CRMD?

Which has stronger earnings & valuation, CRBP or CRMD?

Do analysts recommend CRBP or CRMD?

Does the media prefer CRBP or CRMD?

Which has more volatility and risk, CRBP or CRMD?

Summary

How does Corbus Pharmaceuticals compare to Aclaris Therapeutics?

Which has stronger earnings & valuation, ACRS or CRBP?

Does the media refer more to ACRS or CRBP?

Do institutionals and insiders hold more shares of ACRS or CRBP?

Which has more volatility & risk, ACRS or CRBP?

Is ACRS or CRBP more profitable?

Do analysts recommend ACRS or CRBP?

Summary

How does Corbus Pharmaceuticals compare to CytomX Therapeutics?

Do analysts recommend CTMX or CRBP?

Which has more volatility & risk, CTMX or CRBP?

Do insiders and institutionals have more ownership in CTMX or CRBP?

Does the media favor CTMX or CRBP?

Is CTMX or CRBP more profitable?

Which has better valuation and earnings, CTMX or CRBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools